Key result
Inhibition of nNOS or provision of exogenous NO significantly reduced myocardial ischemic injury across species, an effect exerted downstream of mitoKATP channels and upstream of p38MAPK.
Why the study?
The role and location of neuronal nitric oxide synthase (nNOS) in myocardial ischemic injury and ischemic preconditioning (IP) remain unclear, including its species-dependence and relationship with key IP transduction components.
Does nNOS inhibition or exogenous NO reduce myocardial injury in ischemia/reoxygenation models?
Does nNOS inhibition or exogenous NO reduce myocardial injury in ischemia/reoxygenation models?
nNOS plays a dual role in myocardial ischemia/reoxygenation, where its presence is required for ischemic preconditioning but its inhibition reduces ischemic injury via a p38MAPK-dependent pathway.
Answers are grounded in this paper and cite their sources.
nNOS inhibition may limit ischemic injury yet is required for IP; leaves open targeted modulation in clinical cardioprotection.
BACKGROUND: Nitric oxide (NO) is cardioprotective and a mediator of ischemic preconditioning (IP). Endothelial nitric oxide synthase (eNOS) is protective against myocardial ischemic injury and a component of IP but the role and location of neuronal nitric oxide synthase (nNOS) remains unclear. Therefore, the aims of these studies were to: (i) investigate the role of nNOS in ischemia/reoxygenation-induced injury and IP, (ii) determine whether its effect is species-dependent, and (iii) elucidate the relationship of nNOS with mitoKATP channels and p38MAPK, two key components of IP transduction pathway. RESULTS: Ventricular myocardial slices from rats and wild and nNOS knockout mice, and right atrial myocardial slices from human were subjected to 90 min ischemia and 120 min reoxygenation (37 degrees C). Specimens were randomized to receive various treatments (n = 6/group). Both the provision of exogenous NO and the inhibition of endogenous NO production significantly reduced tissue injury (creatine kinase release, cell necrosis and apoptosis), an effect that was species-independent. The cardioprotection seen with nNOS inhibition was as potent as that of IP, however, in nNOS knockout mice the cardioprotective effect of non-selective NOS (L-NAME) and selective nNOS inhibition and also that of IP was blocked while the benefit of exogenous NO remained intact. Additional studies revealed that the cardioprotection afforded by exogenous NO and by inhibition of nNOS were unaffected by the mitoKATP channel blocker 5-HD, although it was abrogated by p38MAPK blocker SB203580. CONCLUSIONS: nNOS plays a dual role in ischemia/reoxygenation in that its presence is necessary to afford cardioprotection by IP and its inhibition reduces myocardial ischemic injury. The role of nNOS is species-independent and exerted downstream of the mitoKATP channels and upstream of p38MAPK.
No takes yet. Share an insight, caveat, or question.
Barua et al. (2010) studied Myocardial ischemia/reoxygenation injury. nNOS inhibition (TRIM) or exogenous NO (SNAP) vs. Ischemia/reoxygenation alone was evaluated on Creatine kinase release, cell necrosis, and apoptosis (p=<0.05). Inhibition of nNOS or provision of exogenous NO significantly reduced myocardial ischemic injury across species, an effect exerted downstream of mitoKATP channels and upstream of p38MAPK.
Synapse has enriched 10 related papers. Consider them for comparative context: